Malaria in children

The Lancet

Volumn 375, Issue 9724, 2010, Pages 1468-1481

  Crawley, J ^a   Chu, C ^b,c   Nosten, F ^b,c   Mtove, G ^d  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ANGIOPOIETIN 2; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE PLUS MEFLOQUINE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CLINDAMYCIN; DIAZEPAM; DIHYDROARTEMISININ PLUS PIPERAQUINE; EFAVIRENZ; GLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; INSECTICIDE; INTERCELLULAR ADHESION MOLECULE 1; IRON; MALARIA VACCINE; MEFLOQUINE; PHENOBARBITAL; PRIMAQUINE; PYRETHROID; PYRIMETHAMINE; QUINIMAX; QUININE; SULFADOXINE; SULFADOXINE PLUS TRIMETHOPRIM; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ABDOMINAL DISCOMFORT; AFRICA; ANEMIA; ANOPHELES; ANOREXIA; ANTIMALARIAL DRUG RESISTANCE; BACTERIAL INFECTION; BLOOD CULTURE; BLOOD GLUCOSE MONITORING; BLOOD TRANSFUSION; BRAIN DISEASE; BRAIN MALARIA; CELL ADHESION; CHEMOPROPHYLAXIS; CHILD HEALTH; CHILL; COGNITIVE DEFECT; COMA; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONSCIOUSNESS DISORDER; COUGHING; CROSS RESISTANCE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIARRHEA; DISABILITY; DISEASE CARRIER; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG ABSORPTION; DRUG COST; DYSPNEA; EARLY DIAGNOSIS; ENDEMIC DISEASE; ERADICATION THERAPY; ERYTHROCYTE; ERYTHROCYTE CONCENTRATE; FEVER; GASTROENTERITIS; GENE AMPLIFICATION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GLUCOSE BLOOD LEVEL; GOLD STANDARD; HEADACHE; HEART FAILURE; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPOGLYCEMIA; HYPOVOLEMIA; IMMUNITY; INCIDENCE; INFECTION RISK; INFECTION SENSITIVITY; INSECTICIDE RESISTANCE; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; MALARIA; MALARIA CONTROL; MALARIAL RETINOPATHY; MALNUTRITION; METABOLIC ACIDOSIS; MICROSCOPY; MICROVASCULATURE; MIXED INFECTION; MORBIDITY; MORTALITY; MYALGIA; NUTRITIONAL STATUS; OXYGEN THERAPY; PARASITEMIA; PATHOPHYSIOLOGY; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM KNOWLESI MALARIA; PLASMODIUM MALARIAE; PLASMODIUM MALARIAE INFECTION; PLASMODIUM OVALE; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX MALARIA; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RESPIRATORY DISTRESS; RETINOPATHY; RIGOR; RISK ASSESSMENT; RISK REDUCTION; SEIZURE; SEPSIS; TACHYPNEA; THROMBOCYTE; TREATMENT FAILURE; TREATMENT INDICATION; VECTOR CONTROL; VOMITING; ARTICLE; CHILD; COST OF ILLNESS; DEVELOPING COUNTRY; MOSQUITO;

ANTIMALARIALS; CHILD; COST OF ILLNESS; DEVELOPING COUNTRIES; HUMANS; MALARIA; MALARIA VACCINES; MOSQUITO CONTROL;

EID: 77952298888     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60447-3     Document Type: Conference Paper

References (149)

1. Falade C, Mokuolu O, Okafor H, et al. Epidemiology of congenital malaria in Nigeria: a multi-centre study. Trop Med Int Health 2007;12:1279-87.
2. Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox Sang 2006;90:77-84.
3. WHO. World malaria report. 2009. http://www.who.int/malaria/world- malaria-report-2009/en/index.html (accessed Feb. 16, 2010).
4. MAP. Malaria atlas project. http://www.map. ox.ac.uk (accessed Feb. 16, 2010).
5. Snow RW, Hay SI. Comparing methods of estimating the global morbidity burden from Plasmodium falciparum malaria. Am J Trop Med Hyg 2006;74:189-90.
6. Guerra CA, Gikandi PW, Tatem AJ, et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008;5: e38.
7. Hay SI, Guerra CA, Gething PW, et al. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 2009;6: e1000048.
8. Berkley JA, Bejon P, Mwangi T, et al. HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis 2009;49:336-43.
9. Carrara VI, Sirilak S, Thonglairuam J, et al. Deployment of early diagnosis and mefl oquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLoS Med 2006;3: e183.
10. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 2009;22:430-35.
11. Kleinschmidt I, Schwabe C, Benavente L, et al. Marked increase in child survival after four years of intensive malaria control. Am J Trop Med Hyg 2009;80:882-88.
12. Reyburn H, Mbatia R, Drakeley C, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2004;329:1212.
13. O'Meara WP, Mwangi TW, Williams TN, McKenzie FE, Snow RW, Marsh K. Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg 2008;79:185-91.
14. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 2009;48:1704-12.
15. Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008;46:165-71.
16. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007;77(suppl 6):79-87.
17. Kallander K, Nsungwa-Sabiiti J, Peterson S. Symptom overlap for malaria and pneumonia-policy implications for home management strategies. Acta Trop 2004;90:211-14.
18. Caulfi eld LE, Richard SA, Black RE. Undernutrition as an underlying cause of malaria morbidity and mortality in children less than fi ve years old. Am J Trop Med Hyg 2004;71(suppl 2):55-63.
19. WHO. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000;94(suppl 1):1-90.
20. Marsh K, Forster D, Waruiru C, et al. Indicators of lifethreatening malaria in African children. N Engl J Med 1995;332:1399-404.
21. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.
22. Bassat Q, Guinovart C, Sigauque B, et al. Severe malaria and concomitant bacteraemia in children admitted to a rural Mozambican hospital. Trop Med Int Health 2009;14:1011-19.
23. Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med 2004;10:143-45.
24. Crawley J, Smith S, Muthinji P, Marsh K, Kirkham F. Electroencephalographic and clinical features of cerebral malaria. Arch Dis Child 2001;84:247-53.
25. Idro R, Otieno G, White S, et al. Decorticate, decerebrate and opisthotonic posturing and seizures in Kenyan children with cerebral malaria. Malar J 2005;4:5 7.
26. Beare NA, Taylor TE, Harding SP, Lewallen S, Molyneux ME. Malarial retinopathy: a newly established diagnostic sign in severe malaria. Am J Trop Med Hyg 2006;75:790-97.
27. Idro R, Jenkins NE, Newton CRJC. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol 2005;4:827-40.
28. English M, Waruiru C, Marsh K. Transfusion for respiratory distress in life-threatening childhood malaria. Am J Trop Med Hyg 1996;55:525-30.
29. Schellenberg D, Menendez C, Kahigwa E, et al. African children with malaria in an area of intense Plasmodium falciparum transmission: features on admission to the hospital and risk factors for death. Am J Trop Med Hyg 1999;61:431-38.
30. WHO. Management of the child with a serious infection or severe malnutrition. 2000. http://whqlibdoc.who.int/hq/2000/WHO-FCH-CAH-00.1pdf (accessed Feb. 16, 2010).
31. White NJ, Miller KD, Marsh K, et al. Hypoglycaemia in African children with severe malaria. Lancet 1987;1:708-11.
32. Clark IA, Budd AC, Alleva LM, Cowden WB. Human malarial disease: a consequence of infl ammatory cytokine release. Malar J 2006;5:85.
33. Dondorp AM, Pongponratn E, White NJ. Reduced microcirculatory fl ow in severe falciparum malaria: pathophysiology and electron-microscopic pathology. Acta Trop 2004;89:309-17.
34. Planche T, Krishna S. The relevance of malaria pathophysiology to strategies of clinical management. Curr Opin Infect Dis 2005;18:369-75.
35. Marchiafava E, Bignami A. On summer-autumnal fever. London: The New Sydenham Society, 1894.
36. Magowan C, Nunomura W, Waller KL, et al. Plasmodium falciparum histidine-rich protein 1 associates with the band 3 binding domain of ankyrin in the infected red cell membrane. Biochim Biophys Acta 2000;1502:461-70.
37. Turner GD, Morrison H, Jones M, et al. An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol 1994;145:1057-69.
38. Armah H, Dodoo AK, Wiredu EK, et al. High-level cerebellar expression of cytokines and adhesion molecules in fatal, paediatric, cerebral malaria. Ann Trop Med Parasitol 2005;99:629-47.
39. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of infl ammation. Nat Med 2006;12:235-39.
40. Lovegrove FE, Tangpukdee N, Opoka RO, et al. Serum angiopoietin-1 and-2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS One 2009;4: e4912.
41. Medana IM, Turner GD. Human cerebral malaria and the blood-brain barrier. Int J Parasitol 2006;36:555-68.
42. Mishra SK, Newton CR. Diagnosis and management of the neurological complications of falciparum malaria. Nat Rev Neurol 2009;5:189-98.
43. Moxon CA, Heyderman RS, Wassmer SC. Dysregulation of coagulation in cerebral malaria. Mol Biochem Parasitol 2009;166:99-108.
44. Grau GE, Mackenzie CD, Carr RA, et al. Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. J Infect Dis 2003;187:461-66.
45. Dondorp AM, Nyanoti M, Kager PA, Mithwani S, Vreeken J, Marsh K. The role of reduced red cell deformability in the pathogenesis of severe falciparum malaria and its restoration by blood transfusion. Trans R Soc Trop Med Hyg 2002;96:282-86.
46. Dondorp AM, Ince C, Charunwatthana P, et al. Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis 2008;197:79-84.
47. Beare NA, Harding SP, Taylor TE, Lewallen S, Molyneux ME. Perfusion abnormalities in children with cerebral malaria and malarial retinopathy. J Infect Dis 2009;199:263-71.
48. White VA, Lewallen S, Beare NA, Molyneux ME, Taylor TE. Retinal pathology of pediatric cerebral malaria in Malawi. PLoS One 2009;4: e4317.
49. Clark IA, Cowden WB. The pathophysiology of falciparum malaria. Pharmacol Ther 2003;99:221-60.
50. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008;9:725-32.
51. Angulo I, Fresno M. Cytokines in the pathogenesis of and protection against malaria. Clin Diagn Lab Immunol 2002;9:1145-52.
52. Gimenez F, Barraud de Lagerie S, Fernandez C, Pino P, Mazier D. Tumor necrosis factor alpha in the pathogenesis of cerebral malaria. Cell Mol Life Sci 2003;60:1623-35.
53. Lyke KE, Burges R, Cissoko Y, et al. Serum levels of the proinfl ammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12 (p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun 2004;72:5630-37.
54. Day NP, Hien T T, Schollaardt T, et al. The prognostic and pathophysiologic role of pro-and antiinfl ammatory cytokines in severe malaria. J Infect Dis 1999;180:1288-97.
55. Karunaweera ND, Grau GE, Gamage P, Carter R, Mendis KN. Dynamics of fever and serum levels of tumor necrosis factor are closely associated during clinical paroxysms in Plasmodium vivax malaria. Proc Natl Acad Sci USA 1992;89:3200-03.
56. Artavanis-Tsakonas K, Tongren JE, Riley EM. The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin Exp Immunol 2003;133:145-52.
57. Kurtzhals JAL, Adabayeri V, Goka BQ, et al. Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria. Lancet 1998;351:1768-72.
58. Buffet PA, Safeukui I, Milon G, Mercereau-Puijalon O, David PH. Retention of erythrocytes in the spleen: a double-edged process in human malaria. Curr Opin Hematol 2009;16:157-64.
59. Clark IA, Alleva LM. Is human malarial coma caused, or merely deepened, by sequestration? Trends Parasitol 2009;25:314-18.
60. White NJ, Ho M. The pathophysiology of malaria. Adv Parasitol 1992;31:83-173.
61. English M, Sauerwein R, Waruiru C, et al. Acidosis in severe childhood malaria. Q JM 1997;90:263-70.
62. Krishna S, Waller D W, ter Kuile F, et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic signifi cance. Trans R Soc Trop Med Hyg 1994;88:67-73.
63. Maitland K. Severe malaria: lessons learned from the management of critical illness in children. Trends Parasitol 2006;22:457-62.
64. Planche T. Malaria and fl uids-balancing acts. Trends Parasitol 2005;21:562-67.
65. Chandramohan D, Jaff ar S, Greenwood B. Use of clinical algorithms for diagnosing malaria. Trop Med Int Health 2002;7:45-52.
66. White NJ. Antimalarial drug resistance. J Clin Invest 2004;113:1084-92.
67. WHO. Guidelines for the treatment of malaria, 2nd edn. 2010. http://whqlibdoc.who.int/publications/2010/9789241547925-engpdf (accessed Feb. 16, 2010).
68. WHO/Find Diagnostics. Malaria rapid diagnostic test performance: executive summary. Results of WHO product testing of malaria RDTS: round 1 (2008). http://www.fi nddiagnostics.org/export/sites/default/media/press/pdf/ Executive-summarymalaria-RDTspdf (accessed Feb. 16, 2010).
69. Shillcutt S, Morel C, Goodman C, et al. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull World Health Organ 2008;86:101-10.
70. Waltz E. Practical malaria tests promise results in remote regions. Nat Med 2007;13:6.
71. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisininbased combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009;3: CD007483.
72. Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis 2008;46:985-91.
73. German P, Greenhouse B, Coates C, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis 2007;44:889-91.
74. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004;305:1124.
75. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009;361:455-67.
76. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther 2006;80:582-96.
77. Newton PN, Fernandez FM, Plancon A, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in south east Asia. PLoS Med 2008;5: e32.
78. Price RN, Hasugian AR, Ratcliff A, et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother 2007;51:4090-97.
79. Barnes KI, Watkins WM, White NJ. Antimalarial dosing regimens and drug resistance. Trends Parasitol 2008;24:127-34.
80. WHO. World malaria report. 2008. http://www.who.int/malaria/publications/ atoz/9789241563697/en/index.html (accessed Feb. 16, 2010).
81. Pagnoni F. Malaria treatment: no place like home. Trends Parasitol 2009;25:115-19.
82. Global Fund to Fight AIDS, Tuberculosis and Malaria. Aff ordable Medicines Facility-Malaria (AMFm). http://www.theglobalfund.org/en/amfm/ (accessed Feb. 16, 2010).
83. Sabot O, Yeung S, Pagnoni F, et al. Distribution of artemisininbased combination therapies through private sector channels: Lessons from four country case studies. http://www.rff.org/RFF/Documents/RFF-DP-08-43-FINALpdf (accessed Feb. 16, 2010).
84. Bate R, Hess K. Affordable Medicines Facility for malaria. Lancet Infect Dis 2009;9:396-97.
85. Arrow K, Panosian C, Gelband H, eds. Saving lives, buying time: economics of malaria drugs in an age of resistance. Washington, DC: The National Academies Press, 2004.
86. Stoltzfus RJ, Mullany L, Black RE. Iron defi ciency anaemia. In: Ezzati M, Lopez AD, Rodgers A, Murray CJ, eds. Comparative quantifi cation of health risks: global and regional burden of disease attributable to selected major risk factors. Geneva: World Health Organization, 2004.
87. WHO. Guidelines for the use of iron supplements to prevent and treat iron defi ciency anemia. 1998. http://www.who.int/nutrition/publications/ micronutrients/anaemia-iron-defi ciency/1-57881-020-5/en/index.html (accessed Feb. 16, 2010).
88. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis 1997;25:888-95.
89. Iannotti LL, Tielsch JM, Black MM, Black RE. Iron supplementation in early childhood: health benefi ts and risks. Am J Clin Nutr 2006;84:1261-76.
90. Ojukwu JU, Okebe JU, Yahav D, Paul M. Oral iron supplementation for preventing or treating anaemia among children in malariaendemic areas. Cochrane Database Syst Rev 2009;3: CD006589.
91. Gomes MF, Faiz MA, Gyapong JO, et al, for the Study 13 Research Group. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 2009;373:557-66.
92. Molyneux EM, Maitland K. Intravenous fl uids-getting the balance right. N Engl J Med 2005;353:941-44.
93. Berkley JA, Ross A, Mwangi I, et al. Prognostic indicators of early and late death in children admitted to district hospital in Kenya: cohort study. BMJ 2003;326:361.
94. Achoki R, Opiyo N, English M. Mini-review: management of hypoglycaemia in children aged 0-59 months. J Trop Pediatr 2009; published online Nov. 23. DOI:10.1093/tropej/fmp109.
95. Pasvol G, Newton CR, Winstanley PA, et al. Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. Am J Trop Med Hyg 1991;45:702-13.
96. Eisenhut M, Omari AA. Intrarectal quinine for treating Plasmodium falciparum malaria. Cochrane Database Syst Rev 2005;1: CD004009.
97. Mithwani S, Aarons L, Kokwaro GO, et al. Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria. Br J Clin Pharmacol 2004;57:146-52.
98. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005;366:717-25.
99. Lubell Y, Yeung S, Dondorp AM, et al. Cost-effectiveness of artesunate for the treatment of severe malaria. Trop Med Int Health 2009;14:332-37.
100. Rivers EP, Ahrens T. Improving outcomes for severe sepsis and septic shock: tools for early identifi cation of at-risk patients and treatment protocol implementation. Crit Care Clin 2008;24 (suppl 3): S1-47.
101. Berkley JA, Maitland K, Mwangi I, et al. Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study. BMJ 2005;330:995.
102. Bronzan RN, Taylor TE, Mwenechanya J, et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis 2007;195:895-904.
103. Graham SM, English M. Non-typhoidal salmonellae: a management challenge for children with community-acquired invasive disease in tropical African countries. Lancet 2009;373:267-69.
104. English M, Ahmed M, Ngando C, Berkley J, Ross A. Blood transfusion for severe anaemia in children in a Kenyan hospital. Lancet 2002;359:494-95.
105. Maitland K, Pamba A, English M, et al. Pre-transfusion management of children with severe malarial anaemia: a randomised controlled trial of intravascular volume expansion. Br J Haematol 2005;128:393-400.
106. English M. Life-threatening severe malarial anaemia. Trans R Soc Trop Med Hyg 2000;94:585-88.
107. Maitland K, Pamba A, Newton CR, Levin M. Response to volume resuscitation in children with severe malaria. Pediatr Crit Care Med 2003;4:426-31.
108. Namutangula B, Ndeezi G, Byarugaba JS, Tumwine JK. Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: a randomized clinical trial. Malar J 2007;6:138.
109. Boivin MJ, Bangirana P, Byarugaba J, et al. Cognitive impairment after cerebral malaria in children: a prospective study. Pediatrics 2007;119: e360-66.
110. Ngoungou EB, Preux PM. Cerebral malaria and epilepsy. Epilepsia 2008;49(suppl 6):19-24.
111. Idro R, Ndiritu M, Ogutu B, et al. Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA 2007;297:2232-40.
112. Carter JA, Mung'ala-Odera V, Neville BG, et al. Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children. J Neurol Neurosurg Psychiatr 2005;76:476-81.
113. Crawley J, Waruiru C, Mithwani S, et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet 2000;355:701-06.
114. Meremikwu M, Marson AG. Routine anticonvulsants for treating cerebral malaria. Cochrane Database Syst Rev 2002;2: CD002152.
115. Enwere G. A review of the quality of randomized clinical trials of adjunctive therapy for the treatment of cerebral malaria. Trop Med Int Health 2005;10:1171-75.
116. White NJ, Turner RC, Medana IM, Dondorp AM, Day NP. The murine cerebral malaria phenomenon. Trends Parasitol 2010;26:11-15.
117. Meremikwu M, Logan K, Garner P. Antipyretic measures for treating fever in malaria. Cochrane Database Syst Rev 2000;2: CD002151.
118. Greenwood B. The use of antimalarials to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg 2004;71:1-7.
119. McGready R. Intermittent preventive treatment of malaria in infancy. Lancet 2009;374:1478-80.
120. Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009;374:1533-42.
121. WHO. WHO Expert Consultation on cotrimoxazole prophylaxis in HIV infection. 2006. http://www.who.int/hiv/pub/meetingreports/ctx/en/(accessed Feb. 16, 2010).
122. WHO. Report of the technical consultation on intermittent preventive treatment in infants (IPTi). 2009. http://www.who.int/malaria/publications/atoz/ tegconsultiptiapr2009report/en/index.html (accessed Feb. 16, 2010).
123. Gosling RD, Gesase S, Mosha JF, et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebocontrolled trial. Lancet 2009;374:1521-32.
124. Cisse B, Sokhna C, Boulanger D, et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxinepyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 2006;367:659-67.
125. Dicko A, Sagara I, Sissoko MS, et al. Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J 2008;7:123.
126. Kweku M, Liu D, Adjuik M, et al. Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. PLoS One 2008;3: e4000.
127. Sokhna C, Cisse B, Bael H, et al. A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS ONE 2008;3: e1471.
128. Cisse B, Cairns M, Faye E, et al. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One 2009;4: e7164.
129. Clarke SE, Jukes MCH, Njagi JK, et al. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebocontrolled trial. Lancet 2008;372:127-38.
130. Hawley WA, Phillips-Howard PA, ter Kuile FO, et al. Communitywide eff ects of permethrin-treated bed nets on child mortality and malaria morbidity in western Kenya. Am J Trop Med Hyg 2003;68(suppl 4):121-27.
131. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2004;2: CD000363.
132. Gamble C, Ekwaru PJ, Garner P, ter Kuile FO. Insecticide-treated nets for the prevention of malaria in pregnancy: a systematic review of randomised controlled trials. PLoS Med 2007;4: e107.
133. UN General Assembly. Resolution adopted by the General Assembly. 55/2 United Nations Millennium Declaration. http://www.un.org/millennium/declaration/ ares552epdf (accessed Feb. 16, 2010).
134. WHO. Insecticide-treated mosquito nets: a position statement. 2007. http://www.who.int/malaria/publications/atoz/itnspospaperfi nal/en/(accessed Feb. 16, 2010).
135. Carter R, Mendis KN. Evolutionary and historical aspects of the burden of malaria. Clin Microbiol Rev 2002;15:564-94.
136. WHO. Indoor residual spraying: use of indoor residual spraying for scaling up global malaria control and elimination. 2006. http://malaria.who.int/ indoorresidualspraying.html (accessed Feb. 16, 2010).
137. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973;266:169-77.
138. Greenwood B, Targett G. Do we still need a malaria vaccine? Parasite Immunol 2009;31:582-86.
139. Baer K, Klotz C, Kappe SH, Schnieder T, Frevert U. Release of hepatic Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS Pathog 2007;3: e171.
140. Malaria Vaccine Initiative. Life cycle of the malaria parasite: many factors make malaria vaccine development challenging. http://www.malariavaccine. org/malvac-lifecycle.php (accessed Feb. 16, 2010).
141. Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005;366:2012-18.
142. Abdulla S, Oberholzer R, Juma O, et al. Safety and immunogenicity of RTS, S/AS02D malaria vaccine in infants. N Engl J Med 2008;359:2533-44.
143. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008;359:2521-32.
144. Cole-Tobian JL, Michon P, Biasor M, et al. Strain-specifi c duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children. Infect Immun 2009;77:4009-17.
145. Wu Y, Ellis RD, Shaff er D, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008;3: e2636.
146. Dinglasan RR, Jacobs-Lorena M. Flipping the paradigm on malaria transmission-blocking vaccines. Trends Parasitol 2008;24:364-70.
147. Butler D. Initiative targets malaria eradication. Nature 2009;462:19.
148. Saul A, Fay MP. Human immunity and the design of multicomponent, single target vaccines. PLoS One 2007;2: e850.
149. Feachem R, Sabot O. A new global malaria eradication strategy. Lancet 2008;371:1633-35.